名称 | GSK3368715 dihydrochloride |
描述 | GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active and potent inhibitor of type I protein arginine methyltransferases (PRMTs), including PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8. It exhibits anticancer and antitumor activity and can be used to study advanced solid tumors. |
体外活性 | In the majority of 249 cancer cell lines representing 12 tumor types, GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) exhibits 50% or more growth inhibition relative to DMSO-treated cells[1]. |
体内活性 | GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) markedly inhibits the growth of BxPC3 xenografts at all tested doses, achieving tumor growth reductions of 78% and 97% at 150 mg/kg and 300 mg/kg, respectively[1]. |
存储条件 | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : 100 mg/mL (227.55 mM), Sonication is recommended. DMSO : 100 mg/mL (227.55 mM), Sonication is recommended.
|
关键字 | GSK 3368715 | GSK-3368715 Dihydrochloride | EPZ-019997 | EPZ 019997 Dihydrochloride | GSK-3368715 | GSK3368715 Dihydrochloride | EPZ 019997 | EPZ019997 | EPZ-019997 Dihydrochloride | GSK 3368715 Dihydrochloride | GSK3368715 |
相关产品 | BIX-01294 trihydrochloride | Tazemetostat | Piribedil | XY1 | UNC 0631 | GSK126 | EPZ015666 | AMI-1 free acid | MS37452 | MRTX-1719 |